Status:
COMPLETED
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive...
Detailed Description
The study will collect data from eligible patients (six total) and physicians (six total) from one-on-one qualitative interviews and eligible patients from online surveys. Approximately 330 patients w...
Eligibility Criteria
Inclusion
- Physician inclusion criteria
- The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
- The physician has cared for at least ten nmHSPC patients in the past year.
- The physician has experience prescribing NHT and ADT. Patient inclusion criteria
- The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.
Exclusion
- Physician exclusion criteria
- None Patient exclusion criteria
- The patient is castration resistant.
- The patient has metastatic PC.
Key Trial Info
Start Date :
November 22 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 2 2025
Estimated Enrollment :
374 Patients enrolled
Trial Details
Trial ID
NCT06500741
Start Date
November 22 2024
End Date
April 2 2025
Last Update
May 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Analysis Group, Inc.
Boston, Massachusetts, United States, 02199